3-2021

Outcome After Surgical Stabilization of Rib Fractures Versus Nonoperative Treatment in Patients With Multiple Rib Fractures and Moderate to Severe Traumatic Brain Injury (CWIS-TBI)

Jonne T.H. Prins

Esther M. M. Van Lieshout

Francis Ali-Osman

Zachary M. Bauman

Eva-Corina Caragounis

See next page for additional authors

Authors

Jonne T.H. Prins, Esther M. M. Van Lieshout, Francis Ali-Osman, Zachary M. Bauman, Eva-Corina Caragounis, Jeff Choi, D. Benjamin Christie III, Peter A. Cole, William B. DeVoe, Andrew R. Doben, Evert A. Eriksson, Joseph D. Forrester, Douglas R. Fraser, Brendan Gontarz, Claire Hardman, Daniel G. Hyatt, Adam J. Kaye, Huan-Jang Ko, Kiara N. Leasia, Stuart Leon, Silvana F. Marasco, Allison G. McNickle, Timothy Nowack, Terri D. Ogunleye, Prakash Priya, Aaron P. Richman, Victoria Sschlanser, Gregory Semon, Ying-Hao Su, Michael H. J. Verhofstad, Julie Whitis, Fredric M. Pieracci, and Mathieu M. E. Wijffels

Journal of Trauma and Acute Care Surgery, Publish Ahead of Print
DOI: 10.1097/TA.0000000000002994

Outcome after surgical stabilization of rib fractures versus nonoperative treatment in patients with multiple rib fractures and moderate to severe traumatic brain injury (CWIS-TBI)

Jonne T.H. Prins, MD[1], Esther M.M. Van Lieshout, PhD, MSc[1], Francis Ali-Osman, MD, FACS[2], Zachary M. Bauman, DO MHA[3], Eva-Corina Caragounis, MD, PhD[4], Jeff Choi, MD[5], D. Benjamin Christie, III, MD[6], Peter A. Cole, MD[7], William B. DeVoe, MD[8], Andrew R. Doben, MD, FACS[9], Evert A. Eriksson, MD, FACS, FCCP[10], Joseph D. Forrester, MD, MSc[5], Douglas R. Fraser, MD[11], Brendan Gontarz, MD[9], Claire Hardman, RN BSN[12], Daniel G. Hyatt, MD[8], Adam J. Kaye, MD, MHA[13], Huan-Jang Ko, MD[14], Kiara N. Leasia, MD[15], Stuart Leon, MD[10], Silvana F. Marasco, MD[16], Allison G. McNickle, MD[11], Timothy Nowack, MD[6], Temi D. Ogunleye, BSc[17], Prakash Priya, MD[13], Aaron P. Richman, MD[18], Victoria Schlanser, DO MSc[19], Gregory R. Semon, DO, FACS, FACOS[12], Ying-Hao Su, MD[14], Michael H.J. Verhofstad, MD, PhD[1], Julie Whitis, MD[20], Fredric M. Pieracci, MD, MPH[21], Mathieu M.E. Wijffels, MD, PhD[1]

[1] Trauma Research Unit Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands

[2] Department of Surgery, HonorHealth John C. Lincoln Medical Center, Phoenix, AZ 85020, USA

[3] Division of Trauma, Emergency General Surgery, Critical Care Surgery, Department of Surgery, University of Nebraska Medical Center, 983280 Nebraska Medical Center, Omaha, NE 68198-3280, USA

[4] Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

[5] Section of Acute Care Surgery, Department of Surgery, Stanford University, Stanford, CA 94305, USA

[6] Department of Trauma Surgery/Critical Care, Mercer University School of Medicine, The Medical Center Navicent Health, GA 31201, USA

[7] HealthPartners Orthopedics & Sports Medicine, Bloomington, MN 55420, USA; Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN 55455, USA; Department of Orthopaedic Surgery, Regions Hospital, St. Paul, MN 55101, USA

[8] Department of Surgery, Riverside Methodist Hospital, Columbus, 43214 OH, USA

[9] Department of Surgery, Saint Francis Hospital, Hartfort, CT 06105, USA

[10] Division of Trauma and Critical Care, Department of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA

[11] Department of Surgery, UNLV School of Medicine, Las Vegas, NV 89102, USA

[12] Division of Trauma, Department of Surgery, Wright State University/Miami Valley Hospital, Dayton, OH 45409, USA

[13] Department of Surgery, Overland Park Regional Medical Center, Overland Park, KS 66215, USA

[14] Division of Trauma Surgery, Department of Surgery, National Taiwan University Hospital, Hsin-Chu Branch 30059, Hsinchu City, Taiwan

[15] Department of Surgery, Denver Health Medical Center, Denver, CO 80204, USA

[16] CJOB Department of Cardiothoracic Surgery, The Alfred, Melbourne, Australia; Department of Surgery, Monash University, Clayton, Victoria, Australia

[17] Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN 55455, USA; Department of Orthopaedic Surgery, Regions Hospital, St. Paul, MN 55101, USA

[18] Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA , USA.

[19] Department of Trauma/Burn, John H Stroger Hospital of Cook County, Chicago, IL 60612, USA

[20] Department of Surgery, University of Texas Rio Grande Valley, Doctors Hospital at Renaissance, Edinburg, TX 78539, USA

[21] Department of Surgery, Denver Health Medical Center, University of Colorado School of Medicine, Denver, CO 80204, USA

Corresponding author;

Mathieu M.E, Wijffels, MD PhD

Trauma Research Unit Department of Surgery

Erasmus MC, University Medical Center Rotterdam

P.O. Box 2040

3000 CA Rotterdam, The Netherlands

Phone: +31.10.7031050

Fax: +31.10.7032396

Mail: m.wijffels@erasmusmc.nl

E-mail addresses

Jonne T.H. Prins: j.prins@erasmusmc.nl

Esther M.M. Van Lieshout: e.vanlieshout@erasmusmc.nl

Francis Ali-Osman: francisaliosman@gmail.com

Zachary M. Bauman: zachary.bauman@unmc.edu

Eva-Corina Caragounis: eva-corina.caragounis@gu.se

Jeff Choi: jc2226@stanford.edu

Benjamin Christie, III: benjie_christie@yahoo.com

Peter A. Cole: peter.a.cole@healthpartners.com

William B. DeVoe: bidevoe@gmail.com

Andrew R. Doben: andrew.doben@trinityhealthofne.org

Evert A. Eriksson: eriksson@musc.edu

Joseph D. Forrester: jdf1@stanford.edu

Douglas R. Fraser: douglas.fraser@unlv.edu

Brendan Gontarz: gontarz@uchc.edu

Claire Hardman: cehardman@premierhealth.com

Daniel G. Hyatt: daniel.hyatt@ohiohealth.com

Adam J. Kaye: adamjkaye@gmail.com

Huan-Jang Ko: huanjangko@gmail.com

Kiara N. Leasia: kiara.leasia@dhha.org

Stuart Leon: leon@musc.edu

Silvana F. Marasco: s.marasco@alfred.org.au

Allison G. McNickle: allison.mcnickle@unlv.edu

Timothy Nowack: nowack.timothy@navicenthealth.org

Temi D. Ogunleye: temi.ogunleye15@gmail.com

Prakash Priya: prakash.priya91@gmail.com

Aaron P. Richman: aaron.richman@bmc.org

Victoria Schlanser: victoria.schlanser@cookcountyhhs.org

Gregory R. Semon: grsemon@premierhealth.com

Ying-Hao Su: mdsuyinghao@gmail.com

Michael H.J. Verhofstad: m.verhofstad@erasmusmc.nl

Julie Whitis: jwhitis@gmail.com

Fredric M. Pieracci: fredric.pieracci@dhha.org

Mathieu M.E. Wijffels: m.wijffels@erasmusmc.nl

Conflicts of interest

P.A.C. reports grants from DepuySynthes, Stryker, AORF, grants from COTA, AONA, OMeGA, OREF, grants from Zimmer-Biomet, Acumed, personal fees from AO Foundation, other from BoneFoams, Inc, grants from KLS Martin, personal fees from Exactech, personal fees from J&J DepuySynthes, outside the submitted work. A.R.D. is a consultant for Zimmer-Biomet. E.A.E. is a paid speaker for Synthes. S.F.M receives lecture fees from Johnson & Johnson and Zimmer-Biomet. F.M.P. is part of the teaching faculty for KLS-Martin and Zimmer-Biomet. M.M.E.W. and E.M.M.V.L. report grants from the Netherlands Organization for Health Research and Development (ZonMw), DepuySynthes, Stichting Coolsingel, and Ostheosynthesis and Trauma Care Foundation, outside the submitted work. All other authors declare no conflict of interest.

Source of funding

None.

Background: Outcomes after surgical stabilization of rib fractures (SSRF) have not been studied in patients with multiple rib fractures and traumatic brain injury (TBI). We hypothesized that SSRF, as compared to nonoperative management, is associated with favorable outcomes in patients with TBI.

Methods: A multicenter, retrospective cohort study was performed in patients with rib fractures and TBI between January 2012 and July 2019. Patients who underwent SSRF were compared to those managed nonoperatively. The primary outcome was mechanical ventilation-free days. Secondary outcomes were Intensive Care Unit (ICU-LOS) and hospital length of stay (HLOS), tracheostomy, occurrence of complications, neurologic outcome, and mortality. Patients were further stratified into moderate (GCS 9-12) and severe (GCS ≤8) TBI.

Results: The study cohort consisted of 456 patients of which 111 (24.3%) underwent SSRF. SSRF was performed at a median of 3 days and SSRF-related complication rate was 3.6%. In multivariable analyses, there was no difference in mechanical ventilation-free days between the SSRF and nonoperative groups. The odds of developing pneumonia (OR 0.59 (95% CI 0.38-0.98), p=0.043) and 30-day mortality (OR 0.32 (95% CI 0.11-0.91), p=0.032) were significantly lower in the SSRF group. Patients with moderate TBI had similar outcome in both groups. In patients with severe TBI, the odds of 30-day mortality was significantly lower after SSRF (0.19 (95% CI 0.04-0.88), p=0.034).

Conclusions: In patients with multiple rib fractures and TBI, the mechanical ventilation-free days did not differ between the two treatment groups. In addition, SSRF was associated with a

significantly lower risk of pneumonia and 30-day mortality. In patients with moderate TBI, outcome was similar. In patients with severe TBI a lower 30-day mortality was observed. There was a low SSRF-related complication risk. These data suggest a potential role for SSRF in select patients with TBI.

Level of evidence: Therapeutic, level IV

Keywords: Outcome, Surgical Stabilization of Rib Fractures (SSRF), Thoracic Trauma, Traumatic Brain Injury (TBI), Rib Fractures

Introduction

Over 15% of polytraumatized patients have both severe thoracic trauma and traumatic brain injury (TBI) [1]. In the intensive care unit (ICU), rib fractures (42%) and TBI (39%) are the injuries with the highest prevalence [2]. While TBI is the leading cause of mortality, thoracic trauma is listed second and accounts for 25% of injury-related deaths annually [3, 4]. In patients with multiple rib fractures, 15-26% have concurrent TBI; the presence of both injuries is associated with poor outcomes including longer mechanical ventilation and prolonged ICU length of stay [4, 5]. Rib fractures are seen in up to 39% of patients who have sustained blunt thoracic trauma and a debilitation and lethal complication is pneumonia [3]. Rib fractures are associated with pneumonia rates of 17-77%, with increased rates in elderly patients and patients with more rib fractures [6-10]. In addition, the combination of severe thoracic trauma and severe TBI (*i.e.*, an Abbreviated Injury Score (AIS) of 3 or higher) are risk factors for the development of pneumonia which is one of the strongest independent predictors of in-hospital mortality in polytraumatized patients [1].

Due to proven beneficial outcomes in patients with severely displaced rib fractures or flail chest, the use of surgical stabilization of rib fractures (SSRF) has increased considerably over the last decade and has become an important modality in rib fracture management [11-13]. As patients with TBI might confound outcome measures due to an increased risk of prolonged duration of mechanical ventilation, high mortality rate, and complications such as pneumonia, these patients are typically excluded in studies on outcome of SSRF in patients with multiple rib fractures [7, 9, 13, 14]. Also, the unclear prognosis of TBI patients, irrespective of their

underlying thoracic injury, has historically been an exclusion criteria among various studies on the outcome of SSRF. One theoretical concern is that patients with TBI might deteriorate perioperatively due to an increase in intracranial pressure secondary to patient positioning and anesthetics. A survey among thoracic, orthopedic, and trauma surgeons showed that even patients with moderate TBI (Glasgow Coma Scale (GCS) at admission of 9 to 12) were the least likely to be recommended for SSRF, regardless of abnormal pulmonary variables [15]. Thus, while SSRF may be less frequently offered to patients with TBI, the possible benefit of SSRF in this type of patient has not been studied. Specifically, the respiratory benefits achieved by SSRF in the setting of severe chest wall injuries may be of sufficient magnitude to mitigate the negative effects of TBI and ultimately still improve outcomes in this specific patient population.

The primary aim of this study was to determine the effect of SSRF versus nonoperative treatment of rib fractures on the number of ventilator-free days (VFD) in adults who sustained both multiple severe rib fractures and moderate or severe TBI. Secondary aims were to determine the effect of treatment on the ICU length of stay (ICU-LOS), hospital length of stay (HLOS), tracheostomy rate, occurrence of complications, neurological outcome, and (in-hospital and 30-day) mortality. We hypothesized that SSRF is associated with favorable outcomes vs. nonoperative management in patients with co-existing moderate to severe TBI.

Methods

Design and participants

The Chest Wall Injury Society TBI study (CWIS-TBI) was a multicenter, retrospective cohort

study conducted by CWIS and involved 19 trauma centers. The Chest Wall Injury Society is an international surgical society founded in 2016 and comprised of approximately 250 trauma, thoracic, and orthopedic surgeons with a specific interest in the management of chest wall trauma (www.cwisociety.org). Members of CWIS were invited for participation if they expressed interest based on information on the CWIS-website and a personal e-mail consisting of a short and full-length study protocol. After approval for each individual participating center by the local Medical Research Ethics Committee (MREC) or Institutional Review Board (IRB), local investigators identified patients. This was done by searching the hospital's electronic patient files which were registered with specific diagnosis treatment combinations and by searching the national/regional/state trauma registry for admitted patients with a registered Abbreviated Injury Score (AIS) for rib or sternum fractures in combination with an AIS ≥3 of the head. Each hospital used the best local option to identify eligible patients.

Inclusion criteria were: 1) age 18 years or older at time of index trauma; 2) three or more fractures of ribs 3-10 with either a flail chest or bicortical displacement of at least three fractured ribs, as diagnosed on CT-scan; 3) moderate or severe TBI (GCS ≤12 at admission with posttraumatic intracranial changes, as diagnosed on CT-scan); 4) trauma sustained between January 1, 2012 and July 1, 2019; 5) blunt force thoracic trauma; 6) admission to participating hospital within seven days after trauma with documented GCS at first presentation.

Patients with any of the following criteria were excluded: 1) rib fractures due to cardiopulmonary resuscitation; 2) patient unfit for surgery due to hemodynamic instability or patient is moribund; 3) previous rib fractures or pulmonary problems, requiring continuous

oxygen use at home pre-trauma; 4) rib fixation device *in situ* pre-trauma; 5) pre-existing neurological deficit (*i.e.,* GCS ≤12); 6) congenital thoracic deformity; 7) imprisoned at time of trauma; 8) known pregnancy at time of trauma; 9) clinically transferred to other hospital during primary admission; 10) no post-traumatic intracranial changes on brain CT.

Given the exploratory nature of this study and the lack of data on ventilator-free days in the targeted population, a formal sample size calculation was not made.

Data collection and outcome measures

Data were extracted from the patients' electronic medical files. The primary outcome measure was the number of ventilator-free days (VFD) during primary hospital admission, defined as the number of days where the patient breathed without assisted breathing.

Secondary outcome measures were ICU-LOS during primary hospital admission, HLOS for the primary admission, rate of and time to tracheostomy performed, the occurrence of complications (*e.g.*, pneumonia within 30 days after trauma as defined according to the Centers for Disease Control and Prevention (CDC) guidelines [16], pleural empyema as diagnosed on CT-scan within 30 days after trauma and/or pus evacuation [17], and SSRF-related complications such as thoracic bleeding or wound infection), neurological outcome (*i.e.*, if motor GCS (mGCS) = 6 was achieved and number of days recovery since it was first <6), and in-hospital and 30-day mortality (including cause of death).

In addition to the outcome measures, the following data were collected: patient

characteristics (*i.e.*, age, sex, Body Mass Index (BMI) (kg/m^2), smoking at age of trauma, Chronic Obstructive Pulmonary Disease (COPD), and diabetes mellitus) and injury-related variables (*i.e.*, mechanism of injury (high energy (HET) or low energy trauma (LET), type of TBI (epidural hematoma, subdural hematoma (SDH), subarachnoid bleeding (SAB), diffuse axonal injury (DAI), intra-parenchymal hemorrhage, intraventricular hemorrhage (IVH), and brain contusion), TBI severity at hospital admission (moderate (GCS 9-12) or severe (GCS ≤8), intracranial hypertension (ICH) (defined as ICP>20 mm Hg), total number and location of ribs fractured, Injury Severity Score (ISS), presence of a flail chest, pneumothorax, hemothorax, pulmonary contusion, facial fracture, and skull fracture, and presence of at least 3 fractured ribs with bicortical displacement). In addition, the following treatment- and outcome-related variables were collected; treatment (operative or nonoperative), chest tube placement, if operated: surgical delay, rib fixation system used, total number of ribs fixated, ICP reducing therapy performed (including details on the provided therapy), type of additional surgeries required.

Statistical analysis

Data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 25 or higher (SPSS, Chicago, Ill., USA). Normality of continuous variables was tested with the Shapiro-Wilk test, and homogeneity of variances was tested using the Levene's test. A p-value lower than 0.05 was considered statistically significant and all tests were two-sided. Missing data were not imputed since the rate of missing data per variable was <4%, except for "BMI" (13%), "smoking at age of trauma" (28%), and "fracture in every rib region" (11%).

Descriptive analysis was performed in order to report the data for the entire study population and for the treatment groups. Subgroup analysis was performed for the treatment groups, stratified by TBI severity (moderate or severe). For continuous data, the mean and SD (parametric data) or the median and percentiles (non-parametric data) are reported. Statistical significance of differences between SSRF and nonoperative treatment was assessed using Mann-Whitney U-test (non-parametric data). For categorical data, numbers and frequencies are reported per treatment group and compared using Chi-squared or Fisher's Exact test, as applicable.

After univariate analysis, multivariable analysis through logistic regression and linear regression (for binary and continuous outcomes, respectively) was applied in order to control for potential confounding. Potential confounders were selected from literature and from the data of the current study. First a Spearman's rank correlation with outcome measures was determined for the patient demographics and injury characteristics with a known confounding effect (based on literature) or that displayed a p-value of 0.2 or lower in the univariate analysis. Next, the effect of these covariates on the odds ratio (OR) or beta value (for logistic regression and linear regression, respectively) was determined. The covariates with a statistically significant correlation with outcome and/or that had a statistically significant OR or beta value in the regression model were BMI, presence of SDH, SAH, IVH, TBI severity, ICH, number of rib fractures, presence of flail chest, pneumothorax, and pulmonary contusion. Since SDH, SAH, and IVH were likely to reflect TBI severity, only the latter was included in the final regression models. Given the multicenter design of the study, participating center was also considered as a confounder. Study center was however not included in the final model as it did not statistically

correlate with outcome. The final regression model consisted of BMI, TBI severity, presence of ICH, number of rib fractures, presence of flail chest, pneumothorax, and pulmonary contusion. The final crude regression model included the outcome measure as the dependent variable, and SSRF as covariate. In the adjusted analysis, the covariates mentioned above were added as covariates. For binary regression analysis, the OR for SSRF over nonoperative treatment is reported with 95% confidence interval (CI) and p-values. For linear regression analysis, the beta value with 95% CI and p-value is reported.

Results

In total, 456 patients (56.1%) of 813 patients with multiple rib fractures and traumatic TBI were included for analysis (Figure 1). The most common exclusion criterion was unfit (*e.g.*, hemodynamic instability) or moribund patient at hospital admission (n=234). A total of 111 (24.3%) patients were treated with SSRF. The SSRF group had a significantly higher median BMI (28 (P_{25}-P_{75} 25-31) versus 26 (P_{25}-P_{75} 23-29) kg/m^2; p=0.008) than the nonoperative group. Other patient demographics were similar in both treatment groups (Table 1). With regards to the brain injury characteristics, the SSRF group suffered subdural hematoma (n=41, 36.9% versus n=202, 58.6%; p<0.001), subarachnoid hemorrhage (n=60, 54.1% versus n=240, 69.6%; p=0.004), ICH (n=12, 10.8% versus n=89, 26.5%; p<0.001), and severe TBI (n=76, 68.5% versus n=283, 82.0%; p=0.003) significantly less often than the nonoperative group. Brain contusion was more frequently present in the SSRF group (n=26, 23.4% versus n=43, 12.5%; p=0.009; Table 1). The SSRF group required ICP reducing therapy significantly less frequently than the nonoperative group (n=26, 23.4% versus n=146, 42.3%; p<0.001).

The SSRF group sustained a median of 9 (P_{25}-P_{75} 8-12) rib fractures versus 8 (P_{25}-P_{75} 5-11) in the nonoperative group ($p<0.001$) and had a flail chest or pneumothorax more often (n=86, 77.5% versus n=135, 39.9%; $p<0.001$ and n=94, 84.7% versus n=252, 73.0%; p=0.015, respectively). The ISS and rate of performed additional surgeries were similar in both groups. Patients in the subgroups stratified by TBI severity who underwent SSRF had a significantly higher number of rib fractures, more often a flail chest and required a chest tube more often than the nonoperative group (Supplemental Table S1, http://links.lww.com/TA/B829). The nonoperative group with severe TBI had a higher BMI and more often SDH and SAH than the SSRF group (Supplemental Table S1, http://links.lww.com/TA/B829).

SSRF was performed at a median of 3 (P_{25}-P_{75} 2-5) days after admission, and did not differ between the moderate TBI (median 3; P_{25}-P_{75} 1-5 days) and severe TBI group (median 3; P_{25}-P_{75} 2-5 days; p=0.160).

During SSRF, a median of 4 (P_{25}-P_{75} 3-5) ribs were fixated, resulting in a ratio of ribs repaired to fractured (rib fixation ratio) of 0.5 (P_{25}-P_{75} 0.4-0.6). In 39 (36.0%) patients, additional thoracic procedures were performed during SSRF, such as bronchoscopy in 14 (12.6%) patients, VATS in nine (8.1%) patients, diaphragm repair in four (3.6%) patients, pulmonary repair or resection in nine (8.1%) patients and cryoablation in three (2.7%) patients. Complications related to SSRF were seen in four (3.6%) patients and included an intra-operative intracranial pressure increase which required medicinal intervention after which the SSRF was continued in one (0.9%) patient, a post-operative wound infection in two (1.8%) patients and hardware failure in one (0.9%) patient.

Univariate analysis

In the total cohort, 96.7% patients required mechanical ventilation (n=441) of which 85 had moderate TBI (87.6% of the moderate TBI group) and 356 had severe TBI (99.2% of the severe TBI group). For patients with severe TBI, the number of ventilator-free days was significantly higher after SSRF (median 11; P_{25}-P_{75} 7-20 days) than after nonoperative treatment (median 10; P_{25}-P_{75} 1-21 days; p=0.034). The ICU-LOS and HLOS were similar between the two treatment groups in both the total cohort as well as in the subgroups of patients with moderate or severe TBI (Table 2). The rate of pneumonia was significantly lower in both the total cohort as well as in patients with moderate TBI when comparing the SSRF group with the nonoperative group (n=38, 34.2% versus n=164, 47.5%; p=0.016, and n=6, 17.1% versus n=28, 45.2%; p=0.007, respectively). Recovery of mGCS to 6 in patients in which this had been <6 was significantly more frequent in the total cohort and in patients with severe TBI when comparing the SSRF group with the nonoperative group (n=96.2, 93.2% versus n=243, 75.0%; p=0.000 and n=68, 93.2% versus n=272, 72.8%; p<0.001). In the total cohort, this mGCS recovery to 6 was achieved after a median of 3 (P_{25}-P_{75} 1-8) days in the SSRF group versus 4 (P_{25}-P_{75} 2-14) days in the nonoperative group (p=0.020). Both the in-hospital and 30-day mortality rate were significantly lower in the SSRF group in both the total cohort and in patients with severe TBI than in the nonoperative group.

Multivariable analysis

Overall cohort

In the adjusted analysis, the number of ventilator-free days did not differ between the two treatment groups (beta -1.61 (95% CI -6.12 to 2.89) days, p=0.483; Table 2 and Figure 2). The

odds of developing pneumonia (OR 0.59 (95% CI 0.35 to 0.98), p=0.043) and odds of 30-day mortality (OR 0.32 (95% CI 0.11 to 0.91), p=0.032) were significantly lower and rate of mGCS recovery to 6 (beta 4.54 (95% CI 1.77 to 11.69) days, p=0.002) significantly higher in the SSRF group. The ICU-LOS, HLOS, and the other outcome measures were similar in the SSRF and nonoperative group (Tables 2 and 3 and Figure 2).

Moderate TBI

In patients with moderate TBI, the number of ventilator-free days did not differ between the two treatment groups (beta -0.47 (95% CI -9.60 to 8.65) days, p=0.918; Table 2 and Figure 2). The odds of developing pneumonia and of mortality were similar in both treatment groups. No difference in ICU-LOS, HLOS, and the other outcome measures was demonstrated.

Severe TBI

In patients with severe TBI, the number of ventilator-free days was similar in both groups (beta -1.77 (-7.03 to 3.49) days, p=0.508; Table 2 and Figure 2). The odds of 30-day mortality (OR 0.19 (95% CI 0.04-0.88), p=0.034) was significantly lower and the rate of mGCS recovery to 6 (beta 5.95 (95% CI 1.91 to 18.53) days, p=0.002) significantly higher in the SSRF group. The odds of developing pneumonia, the HLOS, ICU-LOS, and the other outcome measures were similar in both treatment groups.

Discussion

This multicenter retrospective cohort study is the first to examine SSRF versus nonoperative treatment on in-hospital outcome in patients with multiple rib fractures and TBI (GCS≤12).

Although there was no difference in the primary outcome of ventilator-free days, this study demonstrated that the SSRF group had, after multivariable analysis, a significantly lower odds of developing pneumonia and of 30-day mortality than the nonoperative group. In patients with severe TBI, SSRF was associated with a significantly lower odds of 30-day mortality. The HLOS, and ICU-LOS were similar in both treatment groups. Furthermore, SSRF in patients with TBI is a safe procedure which can be performed relatively early after admission, without perioperative neurological impairment and a low complication rate.

TBI is considered a traditional contraindication for SSRF as TBI increases the risk of pneumonia regardless of other injuries, as well as the duration of mechanical ventilation, ICU-LOS, and HLOS based on slow neurological recovery. Also, patients with TBI might deteriorate neurologically perioperatively and the neurologic outcome is difficult to predict [12, 13, 18]. Accordingly, the main impediment to ventilator liberation has been traditionally considered to be the TBI as opposed to the chest wall injury, rendering SSRF theoretically of little benefit. Furthermore, no published data are available on the effect of SSRF compared with nonoperative treatment in the patient with TBI. Due to this non-evidence-based consensus, participating centers, while forerunners in the field of SSRF, might have been discrete in performing SSRF at an early stage. However, early (within 48 hours) fixation of rib fractures is associated with shorter duration of mechanical ventilation, HLOS, and ICU-LOS in various patient groups without TBI [14, 19-21].

The mortality rate in patients who sustain TBI is high and known to be approximately 25% in polytraumatized patients [1, 22]. The in-hospital and 30-day mortality rate in the current

study cohort for all nonoperatively treated patients with rib fractures and TBI was 19.7% and 18.6%, respectively. In the entire SSRF group, the mortality rates decreased with 12.5% for in-hospital mortality and 12.3% for 30-day mortality. Patients with severe thoracic injury on CT may have a three times higher odds of 30-day mortality [23]. In this study, after correcting for the TBI severity and presence of ICH, an odds ratio of 0.32 for 30-day mortality for the entire SSRF group and an odds ratio of 0.19 for the SSRF group with severe TBI was found. This indicates a possible beneficial effect of stabilizing the severely injured chest wall by SSRF on the mortality rate of patients with concomitant multiple rib fractures and TBI. Thus, TBI should no longer be seen as a contraindication to SSRF.

Both the presence of TBI and multiple rib fractures are known risk factors for the development of pneumonia [1, 8, 24, 25]. SSRF is known to decrease the rate of pneumonia and has been studied extensively in patients with multiple rib fractures and a flail chest [26, 27]. The SSRF group in this cohort had a median of one additional fractured rib and 37.6% more often a flail chest than the nonoperative group. Although having more severe thoracic injury than the nonoperative group, the rate of pneumonia was 13.3% lower in the SSRF group than in the nonoperative group in the total cohort and 28.1% lower in patients with moderate TBI. After logistic regression, the odds of developing pneumonia in the SSRF group was 0.59 for the total cohort. No effect of SSRF on the pneumonia rate was found in the group with severe TBI. A possible explanation for the lack of this beneficial effect in the SSRF group with severe TBI might be the lengthy mechanical ventilation which these patients often require. This consequently increases the risk of ventilator-associated pneumonia of which rates of 45 to 60% have been found in these patients [28, 29]. Due to the similar number of ventilator-free days in

the SSRF group and nonoperative group of the patients with severe TBI, a comparable rate of ventilator-associated pneumonia could be expected.

While SSRF was associated with significantly lower odds of developing pneumonia and 30-day mortality, the number of ventilator-free days was similar in both groups in the total cohort. As no distinction was made in mechanical ventilation mode, SSRF could have improved respiratory mechanics, allowing for a quicker wean to a less invasive ventilation mode such as pressure support. This might have decreased the odds of developing pneumonia in the SSRF group in this acute phase or decreased pain and consequently added to the prevention of pneumonia after extubation.

In addition, the apparent beneficial effect of SSRF on the odds of developing pneumonia and 30-day mortality in the total study cohort, did not significantly decrease HLOS and ICU-LOS. After correction for the potential confounders, these outcome measures were found to be statistically similar but suggest a modest positive effect of an almost four days decrease for HLOS and two days decrease for ICU-LOS in favor of the SSRF group in the total cohort.

A possible explanation for the similar HLOS and ICU-LOS might be the extensive other injuries of these patients. With a similar rate of additional surgeries performed and a high median ISS of >30 in the SSRF and nonoperative group of the total cohort, the exact effect of these extra-cranial and extra-thoracic injuries on the HLOS and ICU-LOS is unclear.

The current study demonstrated that SSRF in patients with TBI is a safe procedure and

does not introduce additional neurological damage perioperatively. Four out of 111 patients developed a SSRF-related complication of which only one occurred perioperatively. In this patient, ICP increased during positioning in the operating room, but SSRF could successfully be continued after administration of mannitol and reverse-Trendelenburg positioning. In a patient with TBI, factors related to surgery such as fluid resuscitation overload cause an elevating central venous pressure or prone positioning can result in an increasing ICP requiring prompt intervention [30]. While the effect of SSRF has not been specifically studied in patients with TBI, studies have evaluated the effect of timing of orthopedic fracture fixation in patients with TBI. Some of these studies demonstrated deleterious effects of early fracture fixation due to high rates of perioperative hypotension, increased intracranial pressure and poor neurological outcome possibly due to secondary brain injury [31]. On the other hand it is suggested that orthopedic injuries should be managed aggressively while maintaining sufficient cerebral perfusion pressure through adequate monitoring and fluid resuscitation, but supporting literature is not clear and low in quality [32]. In the postoperative setting of this study, no iatrogenic neurological damage was found with similar times to mGCS recovery to 6 in the SSRF group and nonoperative group and a higher rate of mGCS recovery to 6 in the SSRF group of the total cohort and in patients with severe TBI. This outcome measure does not imply that SSRF improves neurological outcome after TBI compared with nonoperative treatment. It does however suggest that SSRF and the appurtenant perioperative setting is safe and does not deteriorate or slow down neurological recovery after TBI, even when SSRF is performed as early as three days after trauma.

The parameter GCS at admission was chosen to define TBI severity as there currently is

no gold standard [33]. The GCS is the most widely used measure of TBI severity [34]. However, while this variable has known limitations (*e.g.*, in intoxicated patients), other parameters such as the AIS Head also have limitations and a weak correlation with long and short term outcome [35, 36]. Due to the retrospective nature of this study, GCS at the time of SSRF or sudden GCS improvements after admission were not known. However, while AIS Head might be a superior indicator for defining TBI severity, which should be evaluated in future research, the GCS is one of the best severity measurements for immediate clinical care [37]. In order to correct for non-traumatic reasons leading to a lowered GCS, the combination of GCS and presence of intracranial abnormalities on head CT was chosen as an inclusion criterion. This was readily available for all participating centers and of clinical importance during the early post-traumatic phase as SSRF performed within 48 hours is associated with improved outcome [19]. In addition, the logistic regression analysis abstracted and controlled for parameters beyond GCS that captured severity of TBI, such as the presence of ICH.

While this cohort study is the first, to date, to evaluate the effect of SSRF on in-hospital outcome in patients with multiple rib fractures and TBI, several limitations should be considered when interpreting the outcome.

First, due to the retrospective nature of this study, missing data and underreporting might have affected outcome through information bias. Through data collection in which all variables were obligatory and low-threshold communication as the providing co-authors were CWIS members, there were hardly any missing data concerning the included patients.

Second, while the multicenter design resulted in a large number of patients, the sample size of subgroups might have been too low to detect small but clinically meaningful differences in outcome between treatment groups. As lower sample size result in larger confidence intervals, this may explain why the lower odds of developing pneumonia found for the total SSRF group was not seen for the moderate and severe TBI subgroups. The size of the total cohort was unclear beforehand. Therefore the use of an adjusted regression model was chosen instead of propensity score matching. The multicenter design might also have affected outcome due to heterogeneity in clinical practice resulting in effect modification or potential confounding of within-center covariates [38]. On the other hand, the multicenter design has made the results more generalizable.

Third, the study was non-randomized. The mortality difference between the SSRF and nonoperative group might therefore be suggestive of the fact that patients with a better neurological status and consequently prognosis, are more likely to be selected for SSRF, confounding this outcome. With no standardized treatment protocol and the more severe TBI characteristics in the nonoperative group, the treating clinician might have chosen to perform SSRF on the patient in which a better outcome and prognosis was expected. This might have introduced some bias in the outcome, but mimics daily clinic. A possible consequent survival bias was however mitigated by using the number of ventilator-free days instead of the duration of mechanical ventilation as the primary outcome and by performing a linear regression analysis.

Fourth, the presented logistic and linear regression model only included possible confounders which were identified from available literature and the current data. The

confounding effect of non-included parameters, such as AIS Head, is therefore not known. A prospective design with set variables and a standardized treatment protocol might overcome these shortcomings. In addition, due to the retrospective data on in-hospital outcome, future research should focus on the outcome after discharge and cost effectiveness in order to provide a complete overview on outcome after SSRF in this type of patient. Prior to conducting expensive and potentially risky prospective studies, such as randomized controlled trials (RCTs), on this issue, it is important to establish through retrospective research that there is, as this study showed, at least equipoise and, specifically, that SSRF does not harm patients with TBI.

In summary, in patients with moderate to severe TBI a difference in the primary outcome of number of ventilator-free days between the SSRF and nonoperative groups was not demonstrated. However, this exploratory study suggests a reduced odds of both pneumonia and 30-day mortality in patients who underwent SSRF as compared to nonoperative treatment. Moreover, SSRF is shown to be a safe procedure with a low complication rate, and TBI should no longer be seen as an absolute contra-indication to surgery. Prospective studies should strengthen this conclusion in future research.

Acknowledgments

The current work did not receive any financial funding. We would like to thank SarahAnn Whitbeck, MBA, FACEHP, CHCP (executive director of CWIS), for her time and effort in setting up this study. We would like to thank John Buchanan, BSc (Mercer University School of Medicine), Chun-Hsiung Huang, MD (National Taiwan University Hospital), Jeffrey Skubic, DO, and Raul Barreda, MD (University of Texas Rio Grande Valley), and Michelle Woodfall and Denise Greci (Stanford University), for their effort in the data collection and other study-related activities.

Authorship

J.T.H.P., E.M.M.V.L., F.M.P., and M.M.E.W. participated in the study design. J.T.H.P., E.M.M.V.L., F.A., Z.M.B., E.C., J.C., D.B.C., P.A.C.,W.B.D., A.R.D., E.A.E., J.D.F., D.R.F., B.G., C.H., D.G.H., A.J.K., H.K., K.N.L., S.L., S.F.M., A.G.M., T.N., T.D.O., P.P., A.P.R., V.S., G.R.S., Y.S., J.W., F.M.P., and M.M.E.W participated in data collection. J.T.H.P., E.M.M.V.L., and M.M.E.W. participated in data analysis. J.T.H.P., E.M.M.V.L., F.M.P., and M.M.E.W. participated in data interpretation. J.T.H.P., E.M.M.V.L., and M.M.E.W. participated in manuscript development. J.T.H.P., E.M.M.V.L., F.A., Z.M.B., E.C., J.C., D.B.C., P.A.C.,W.B.D., A.R.D., E.A.E., J.D.F., D.R.F., B.G., C.H., D.G.H., A.J.K., H.K., K.N.L., S.L., S.F.M., A.G.M., T.N., T.D.O., P.P., A.P.R., V.S., G.R.S., Y.S., M.H.J.V., J.W., F.M.P., and M.M.E.W participated in critical revisions and accepted the final manuscript version.

Disclosures

P.A.C. reports grants from DepuySynthes, Stryker, AORF, grants from COTA, AONA,

OMeGA, OREF, grants from Zimmer-Biomet, Acumed, personal fees from AO Foundation, other from BoneFoams, Inc, grants from KLS Martin, personal fees from Exactech, personal fees from J&J DepuySynthes, outside the submitted work. A.R.D. is a consultant for Zimmer-Biomet. E.A.E. is a paid speaker for Synthes. S.F.M receives lecture fees from Johnson & Johnson and Zimmer-Biomet. F.M.P. is part of the teaching faculty for KLS-Martin and Zimmer-Biomet. M.M.E.W. and E.M.M.V.L. report grants from the Netherlands Organization for Health Research and Development (ZonMw), DepuySynthes, Stichting Coolsingel, and Ostheosynthesis and Trauma Care Foundation, outside the submitted work. All other authors declare no conflict of interest.

Funding

No funding was provided for this study.

References

1. Hofman M, Andruszkow H, Kobbe P, Poeze M, Hildebrand F. Incidence of post-traumatic pneumonia in poly-traumatized patients: identifying the role of traumatic brain injury and chest trauma. *Eur J Trauma Emerg Surg*. 2020;46(1):11-9.
2. Michetti CP, Fakhry SM, Brasel K, Martin ND, Teicher EJ, Newcomb A, group Ts. Trauma ICU Prevalence Project: the diversity of surgical critical care. *Trauma Surg Acute Care Open*. 2019;4(1):e000288.
3. Lafferty PM, Anavian J, Will RE, Cole PA. Operative treatment of chest wall injuries: indications, technique, and outcomes. *J Bone Joint Surg Am*. 2011;93(1):97-110.
4. Ziegler DW, Agarwal NN. The morbidity and mortality of rib fractures. *J Trauma*. 1994;37(6):975-9.
5. Dehghan N, de Mestral C, McKee MD, Schemitsch EH, Nathens A. Flail chest injuries: a review of outcomes and treatment practices from the National Trauma Data Bank. *J Trauma Acute Care Surg*. 2014;76(2):462-8.
6. Tanaka H, Yukioka T, Yamaguti Y, Shimizu S, Goto H, Matsuda H, Shimazaki S. Surgical stabilization of internal pneumatic stabilization? A prospective randomized study of management of severe flail chest patients. *J Trauma*. 2002;52(4):727-32; discussion 32.
7. Marasco SF, Davies AR, Cooper J, Varma D, Bennett V, Nevill R, Lee G, Bailey M, Fitzgerald M. Prospective randomized controlled trial of operative rib fixation in traumatic flail chest. *J Am Coll Surg*. 2013;216(5):924-32.
8. Bulger EM, Arneson MA, Mock CN, Jurkovich GJ. Rib fractures in the elderly. *J Trauma*. 2000;48(6):1040-6; discussion 6-7.

9. Qiu M, Shi Z, Xiao J, Zhang X, Ling S, Ling H. Potential benefits of rib fracture fixation in patients with flail chest and multiple non-flail rib fractures. *Indian J Surg*. 2016;78(6):458-63.
10. Bergeron E, Lavoie A, Clas D, Moore L, Ratte S, Tetreault S, Lemaire J, Martin M. Elderly trauma patients with rib fractures are at greater risk of death and pneumonia. *J Trauma*. 2003;54(3):478-85.
11. Kane ED, Jeremitsky E, Pieracci FM, Majercik S, Doben AR. Quantifying and exploring the recent national increase in surgical stabilization of rib fractures. *J Trauma Acute Care Surg*. 2017;83(6):1047-52.
12. Pieracci FM, Majercik S, Ali-Osman F, Ang D, Doben A, Edwards JG, French B, Gasparri M, Marasco S, Minshall C, et al. Consensus statement: Surgical stabilization of rib fractures rib fracture colloquium clinical practice guidelines. *Injury*. 2017;48(2):307-21.
13. Kasotakis G, Hasenboehler EA, Streib EW, Patel N, Patel MB, Alarcon L, Bosarge PL, Love J, Haut ER, Como JJ. Operative fixation of rib fractures after blunt trauma: A practice management guideline from the Eastern Association for the Surgery of Trauma. *J Trauma Acute Care Surg*. 2017;82(3):618-26.
14. Althausen PL, Shannon S, Watts C, Thomas K, Bain MA, Coll D, O'Mara T J, Bray TJ. Early surgical stabilization of flail chest with locked plate fixation. *J Orthop Trauma*. 2011;25(11):641-7.
15. Pieracci FM, Agarwal S, Doben A, Shiroff A, Lottenberg L, Whitbeck SA, White TW. Indications for surgical stabilization of rib fractures in patients without flail chest: surveyed opinions of members of the Chest Wall Injury Society. *Int Orthop*. 2018;42(2):401-8.
16. Prevention TCoDCa. Pneumonia (Ventilator-associated [VAP] and non-ventilator-

associated Pneumonia [PNEU]) Event 2018 [Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf.

17. DuBose J, Inaba K, Okoye O, Demetriades D, Scalea T, O'Connor J, Menaker J, Morales C, Shiflett T, Brown C, et al. Development of posttraumatic empyema in patients with retained hemothorax: results of a prospective, observational AAST study. *J Trauma Acute Care Surg*. 2012;73(3):752-7.
18. De Campos JRM, White TW. Chest wall stabilization in trauma patients: why, when, and how? *J Thorac Dis*. 2018;10(Suppl 8):S951-S62.
19. Pieracci FM, Coleman J, Ali-Osman F, Mangram A, Majercik S, White TW, Jeremitsky E, Doben AR. A multicenter evaluation of the optimal timing of surgical stabilization of rib fractures. *J Trauma Acute Care Surg*. 2018;84(1):1-10.
20. Iqbal HJ, Alsousou J, Shah S, Jayatilaka L, Scott S, Scott S, Melling D. Early Surgical Stabilization of Complex Chest Wall Injuries Improves Short-Term Patient Outcomes. *J Bone Joint Surg Am*. 2018;100(15):1298-308.
21. Otaka S, Aso S, Matsui H, Fushimi K, Yasunaga H. Early versus late rib fixation in patients with traumatic rib fractures: a nationwide study. *Ann Thorac Surg.* 2020.
22. van Leeuwen N, Lingsma HF, Perel P, Lecky F, Roozenbeek B, Lu J, Shakur H, Weir J, Steyerberg EW, Maas AI, et al. Prognostic value of major extracranial injury in traumatic brain injury: an individual patient data meta-analysis in 39,274 patients. *Neurosurgery*. 2012;70(4):811-8; discussion 8.
23. Dai D, Yuan Q, Sun Y, Yuan F, Su Z, Ding J, Tian H. Impact of thoracic injury on traumatic brain injury outcome. *PLoS One*. 2013;8(9):e74204.
24. Coary R, Skerritt C, Carey A, Rudd S, Shipway D. New horizons in rib fracture

management in the older adult. *Age Ageing*. 2019.

25. Flagel BT, Luchette FA, Reed RL, Esposito TJ, Davis KA, Santaniello JM, Gamelli RL. Half-a-dozen ribs: the breakpoint for mortality. *Surgery*. 2005;138(4):717-23; discussion 23-5.
26. Beks RB, Peek J, de Jong MB, Wessem KJP, Oner CF, Hietbrink F, Leenen LPH, Groenwold RHH, Houwert RM. Fixation of flail chest or multiple rib fractures: current evidence and how to proceed. A systematic review and meta-analysis. *Eur J Trauma Emerg Surg*. 2018.
27. Cataneo AJ, Cataneo DC, de Oliveira FH, Arruda KA, El Dib R, de Oliveira Carvalho PE. Surgical versus nonsurgical interventions for flail chest. *Cochrane Database Syst Rev*. 2015(7):CD009919.
28. Esnault P, Nguyen C, Bordes J, D'Aranda E, Montcriol A, Contargyris C, Cotte J, Goutorbe P, Joubert C, Dagain A, et al. Early-Onset Ventilator-Associated Pneumonia in Patients with Severe Traumatic Brain Injury: Incidence, Risk Factors, and Consequences in Cerebral Oxygenation and Outcome. *Neurocrit Care*. 2017;27(2):187-98.
29. Zygun DA, Zuege DJ, Boiteau PJ, Laupland KB, Henderson EA, Kortbeek JB, Doig CJ. Ventilator-associated pneumonia in severe traumatic brain injury. *Neurocrit Care*. 2006;5(2):108-14.
30. Hariri RJ, Firlick AD, Shepard SR, Cohen DS, Barie PS, Emery JM, Ghajar JBG. Traumatic Brain Injury, Hemorrhagic-Shock, and Fluid Resuscitation - Effects on Intracranial-Pressure and Brain Compliance. *J Neurosurg*. 1993;79(3):421-7.
31. O'Brien PJ. Fracture fixation in patients having multiple injuries. *Can J Surg*. 2003;46(2):124-8.

32. Giannoudis PV, Veysi VT, Pape HC, Krettek C, Smith MR. When should we operate on major fractures in patients with severe head injuries? *Am J Surg*. 2002;183(3):261-7.
33. Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. *Lancet Neurol*. 2014;13(8):844-54.
34. The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Glasgow coma scale score. *J Neurotrauma*. 2000;17(6-7):563-71.
35. Foreman BP, Caesar RR, Parks J, Madden C, Gentilello LM, Shafi S, Carlile MC, Harper CR, Diaz-Arrastia RR. Usefulness of the abbreviated injury score and the injury severity score in comparison to the Glasgow Coma Scale in predicting outcome after traumatic brain injury. *J Trauma*. 2007;62(4):946-50.
36. Demetriades D, Kuncir E, Murray J, Velmahos GC, Rhee P, Chan L. Mortality prediction of head Abbreviated Injury Score and Glasgow Coma Scale: analysis of 7,764 head injuries. *J Am Coll Surg*. 2004;199(2):216-22.
37. Savitsky B, Givon A, Rozenfeld M, Radomislensky I, Peleg K. Traumatic brain injury: It is all about definition. *Brain Inj*. 2016;30(10):1194-200.
38. Localio AR, Berlin JA, Ten Have TR, Kimmel SE. Adjustments for center in multicenter studies: an overview. *Ann Intern Med*. 2001;135(2):112-23.

Figure legends

Figure 1: Flow chart of the study

Figure 2: Forrest plots for the effect of SSRF over nonoperative treatment for (A) continuous and (B) binary outcomes in all patients as well as in patients with moderate or severe TBI, based on (un)adjusted regression models

Unadjusted and adjusted beta values and Odds Ratio's (for continuous and binary outcomes, respectively) are shown. For binary outcomes, nonoperative treatment served as reference group. In the adjusted analysis, body mass index (BMI), TBI severity, intracranial hypertension (ICH), number of rib fractures, flail chest, pneumothorax, and pulmonary contusion were entered as covariate.

Table legends

Table 1: Demographics and injury characteristics of patients with moderate or severe TBI and rib fractures treated operatively (SSRF) or nonoperatively

BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; GCS, Glasgow Coma Scale; ICP, intracranial pressure; SSRF, surgical stabilization of rib fractures; TBI, traumatic brain injury.

*: provides the exact number of patients for which the parameter was known

Data are shown as median (P_{25}-P_{75}) or as N (%); bold p-values are considered statistically significant.

Table 2: Univariate and multivariable in-hospital outcome of SSRF versus nonoperative treatment in patients with rib fractures and moderate or severe TBI

CI, confidence interval; HLOS, hospital length of stay; ICU-LOS, Intensive Care Unit length of stay; mGCS, motor Glasgow Coma Scale; N.D., not determined; OR, odds ratio; SSRF, surgical stabilization of rib fractures; TBI, traumatic brain injury.

*: provides the exact number of patients for which the outcome measure was known. The multivariable analysis shows the effect of SSRF over nonoperative treatment. In the adjusted analysis, body mass index (BMI), TBI severity, intracranial hypertension (ICH), number of rib fractures, flail chest, pneumothorax, and pulmonary contusion were entered as covariate.

ORs and beta values are shown with 95% confidence interval; bold p-values are considered statistically significant.

Table 3 In-hospital outcome in patients with moderate or severe TBI and rib fractures treated operatively (SSRF) or nonoperatively

FU, follow-up; ICP; intracranial pressure; mGCS, motor Glasgow Coma Scale; Nonop, nonoperative treatment; SEPS; subdural evacuation port system; SSRF, surgical stabilization of

rib fractures; ICP, intracranial pressure; TBI; traumatic brain injury.

*: provides the exact number of patients for which the outcome measure was known.

Data are shown as N (%), mean (SD), or as median (P_{25}-P_{75}); bold p-values are considered statistically significant

Supplemental Table S1: Demographics and injury characteristics of patients with moderate (GCS 9-12) or severe (GCS ≤8) traumatic brain injury (TBI) and rib fractures treated operatively (SSRF) or nonoperatively

BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; GCS, Glasgow Coma Scale; ICP, intracranial pressure; N.D., not determined; SEPS, subdural evacuation port system; SSRF, surgical stabilization of rib fractures; TBI, traumatic brain injury.

*: provides the exact number of patients for which the parameter was known

Data are shown as mean (SD), N (%), or as median (P_{25}-P_{75}); bold p-values are considered statistically significant.

Figure 1



Figure 2



Table 1: Demographics and injury characteristics of patients with moderate or severe TBI and rib fractures treated operatively (SSRF) or nonoperatively

	N*	Overall (n=456)	N*	SSRF (n=111)	N*	Nonoperative (n=345)	P-value
Patient characteristics							
Age (years)	456	50 (37-63)	111	50 (37-61)	345	50 (37-63)	0.786
Sex (male)	455	349 (76.7%)	110	80 (72.7%)	345	269 (78.0%)	0.300
BMI (kg/m^2)	398	26 (24-30)	100	28 (25-31)	298	26 (23-29)	**0.008**
Smoking at age of trauma	328	131 (39.9%)	83	38 (45.8%)	245	93 (38.0%)	0.243
COPD	456	27 (5.9%)	111	11 (9.9%)	345	16 (4.6%)	0.061
Diabetes Mellitus	456	49 (10.7%)	111	14 (12.6%)	345	35 (10.1%)	0.482
Injury characteristics							
High-energy trauma (HET)	450	408 (90.7%)	110	100 (90.9%)	340	308 (90.6%)	1.000
Epidural hematoma	456	38 (8.3%)	111	6 (5.4%)	345	32 (9.3%)	0.239
Subdural hematoma	456	243 (53.3%	111	41 (36.9%)	345	202 (58.6%)	**<0.001**
Subarachnoid hemorrhage	456	300 (65.8%)	111	60 (54.1%)	345	240 (69.6%)	**0.004**
Diffuse axonal injury (DAI)	456	90 (19.7%)	111	21 (18.9%)	345	69 (20.0%)	0.891
Intra-parenchymal hemorrhage	456	132 (28.9%)	111	34 (30.6)	345	98 (28.4%)	0.718
Intraventricular hemorrhage	456	40 (8.8%)	111	5 (4.5%)	345	35 (10.1%)	0.082
Brain contusion	456	69 (15.1%)	111	26 (23.4%)	345	43 (12.5%)	**0.009**
TBI severity at admission	456		111		345		
Moderate (GCS 9-12)		97 (21.3%)		35 (31.5%)		62 (18.0%)	**0.003**
Severe (GCS $\leq$ 8))		359 (78.7%)		76 (68.5%)		283 (82.0%)	
Intracranial hypertension (ICH)	447	101 (22.6%)	111	12 (10.8%)	336	89 (26.5%)	**<0.001**
Number of ribs fractured	456	8 (6-11)	111	9 (8-12)	345	8 (5-11)	**<0.001**
Injury Severity Score (ISS)	456	34 (27-41)	111	33 (27-41)	345	34 (27-41)	0.938
Additional injury							
Flail chest	449	221 (49.2%)	111	86 (77.5%)	338	135 (39.9%)	**<0.001**

Pneumothorax	456	346 (75.9%	111	94 (84.7%)	345	252 (73.0%)	**0.015**
Hemothorax	454	246 (54.2%)	110	67 (60.9%)	344	179 (52.0%)	0.124
Pulmonary contusion	452	337 (74.6%)	111	85 (76.6%)	341	252 (73.9%)	0.617
Facial fracture	456	169 (37.1%)	111	41 (36.9%)	345	128 (37.1%)	1.000
Skull fracture	455	186 (40.9%)	111	42 (37.8%)	344	144 (41.9%)	0.506
Fracture in every rib region	405	141 (34.8%)	100	48 (48.0%)	305	93 (30.5%)	**0.002**
≥100% displacement of ≥3 ribs	441	301 (68.3%)	109	81 (74.3%)	332	220 (66.3%)	0.125
Treatment characteristics							
Chest tube required	456	330 (72.4%)	111	99 (89.2%)	345	231 (67.0%)	**<0.001**
ICP reducing therapy required	456	172 (37.7%)	111	26 (23.4%)	345	146 (42.3%)	**<0.001**
Additional surgeries performed							
Facial surgery	456	34 (7.5%)	111	13 (11.7%)	345	21 (6.1%)	0.061
Clavicle surgery	456	16 (3.5%)	111	8 (7.2%)	345	8 (2.3%)	**0.032**
Thoracotomy	456	19 (4.2%)	111	8 (7.2%)	345	11 (3.2%)	0.096
Laparotomy	456	54 (11.8%)	111	11 (9.9%)	345	43 (12.5%)	0.612
Pelvic surgery	456	46 (10.1%)	111	11 (9.9%)	345	35 (10.1%)	1.000
Long bone surgery	456	109 (23.9%)	111	33 (29.7%)	345	76 (22.0%)	0.124
Spine surgery	456	45 (10.1%)	111	6 (5.4%)	345	40 (11.6%)	0.070

BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; GCS, Glasgow Coma Scale; ICP, intracranial pressure; SSRF, surgical stabilization of rib fractures; TBI, traumatic brain injury.

*: provides the exact number of patients for which the parameter was known

Data are shown as median (P_{25}-P_{75}) or as N (%); bold p-values are considered statistically significant.

Table 2: Univariate and multivariable in-hospital outcome of SSRF versus nonoperative treatment in patients with rib fractures and moderate or severe TBI

Outcome	Univariate analysis					Multivariable analysis					
	SSRF		Nonoperative				Crude analysis			Adjusted analysis	
	N*		N*		P-value	N*	Beta or OR (95% CI)	P-value	N*	Beta or OR (95% CI)	P-value
Ventilator-free days											
All	111	11 (7-20)	345	10 (1-21)	0.069	456	-0.53 (-4.27 to 3.21)	0.781	381	-1.61 (-6.12 to 2.89)	0.483
Moderate TBI	35	12 (7-18)	62	10 (5-23)	0.523	97	-1.95 (-8.67 to 4.77)	0.566	79	-0.47 (-9.60 to 8.65)	0.918
Severe TBI	76	11 (7-20)	283	10 (1-21)	**0.034**	359	0.14 (-4.39 to 4.67)	0.952	302	-1.77 (-7.03 to 3.49)	0.508
ICU-LOS											
All	111	12 (7-19)	345	14 (7-22)	0.209	456	-2.23 (-4.67 to 0.01)	0.051	381	-2.03 (-4.56 to 0.49)	0.114
Moderate TBI	35	8 (5-15)	62	12 (5-15)	0.209	97	-2.96 (-6.79 to 0.87)	0.128	79	-1.83 (-5.72 to 2.07)	0.353
Severe TBI	76	14 (8-20)	283	14 (7-22)	0.824	359	-1.23 (-3.93 to 1.47)	0.373	302	-1.86 (-4.92 to 1.21)	0.234
HLOS											
All	111	21 (14-32)	345	22 (13-38)	0.990	456	-2.82 (-7.29 to 1.65)	0.215	381	-3.82 (-9.15 to 1.51)	0.159
Moderate TBI	35	19 (13-24)	62	19 (13-30)	0.784	97	-5.43 (-13.11 to 2.24)	0.163	79	-4.84 (-14.73 to 5.06)	0.333
Severe TBI	76	23 (16-34)	283	23 (13-39)	0.536	359	-0.99 (-6.43 to 4.45)	0.721	302	-3.11 (-9.43 to 3.22)	0.334
Pneumonia											
All	111	38 (34.2%)	345	164 (47.5%)	**0.016**	456	0.58 (0.37 to 0.90)	**0.015**	381	0.59 (0.35 to 0.98)	**0.043**
Moderate TBI	35	6 (17.1%)	62	28 (45.2%)	**0.007**	97	0.25 (0.09 to 0.69)	**0.007**	79	0.35 (0.11 to 1.14)	0.082
Severe TBI	76	32 (42.1%)	283	136 (48.1%)	0.368	359	0.79 (0.47 to 1.31)	0.357	302	0.69 (0.39 to 1.25)	0.221
mGCS recovery to 6											

All	103	96 (93.2%)	324	243 (75.0%)	**<0.001**	427	4.57 (2.04 to 10.25)	**<0.001**	356	4.54 (1.77 to 11.69)	**0.002**
Moderate TBI	30	28 (93.3%)	52	45 (86.5%)	0.475	82	2.18 (0.42 to 11.24)	0.353	65	N.D.	N.D.
Severe TBI	73	68 (93.2%)	272	198 (72.8%)	**<0.001**	345	5.08 (1.97 to 13.10)	**0.001**	291	5.95 (1.91 to 18.53)	**0.002**
In-hospital mortality											
All	111	8 (7.2%)	345	68 (19.7%)	**0.002**	456	0.32 (0.15 to 0.68)	**0.003**	381	0.40 (0.15 to 1.04)	0.061
Moderate TBI	35	4 (11.4%)	62	9 (14.5%)	0.765	97	0.76 (0.22 to 2.68)	0.669	79	N.D.	N.D.
Severe TBI	76	4 (5.3%)	283	59 (20.8%)	**0.001**	359	0.21 (0.07 to 0.60)	**0.004**	302	0.30 (0.08 to 1.06)	0.061
30-day mortality											
All	111	7 (6.3%)	345	64 (18.6%)	**0.001**	456	0.30 (0.13 to 0.67)	**0.003**	381	0.32 (0.11 to 0.91)	**0.032**
Moderate TBI	35	4 (11.4%)	62	9 (14.5%)	0.765	97	0.76 (0.22 to 2.68)	0.669	79	N.D.	N.D.
Severe TBI	76	3 (3.9%)	283	55 (19.4%)	**0.001**	359	0.17 (0.05 to 0.56)	**0.004**	302	0.19 (0.04 to 0.88)	**0.034**

CI, confidence interval; HLOS, hospital length of stay; ICU-LOS, Intensive Care Unit length of stay; mGCS, motor Glasgow Coma Scale; N.D., not determined; OR, odds ratio; SSRF, surgical stabilization of rib fractures; TBI, traumatic brain injury.

*: provides the exact number of patients for which the outcome measure was known. The multivariable analysis shows the effect of SSRF over nonoperative treatment. In the corrected analysis, body mass index (BMI), TBI severity, intracranial hypertension (ICH), number of rib fractures, flail chest, pneumothorax, and pulmonary contusion were entered as covariate.

ORs and beta values are shown with 95% confidence interval; bold p-values are considered statistically significant.

Table 3 In-hospital outcome in patients with moderate or severe TBI and rib fractures treated operatively (SSRF) or nonoperatively

		All			Moderate TBI			Severe TBI		
	N*	**SSRF (n = 111)**	**Nonop. (n = 345)**	**P-value**	**SSRF (n = 35)**	**Nonop. (n = 62)**	**P-value**	**SSRF (n = 76)**	**Nonop. (n = 62)**	**P-value**
Tracheostomy performed	456	35 (31.5%)	135 (39.1%)	0.176	6 (17.1%)	16 (25.8%)	0.450	29 (38.2%)	119 (42.0%)	0.600
Time to tracheostomy (days)	456	9 (5-12)	10 (7-15)	0.125	5.8 (SD 4.2)	10.0 (SD 5.2)	0.120	10 (6-13)	11 (7-15)	0.363
Pleural empyema	456	1 (0.9%)	5 (1.4%)	1.000	1 (2.9%)	1 (1.6%)	1.000	0 (0.0%)	4 (1.4%)	0.583
Time until mGCS=6 (days)	456	3 (1-8)	4 (2-14)	**0.020**	2 (1-4)	3 (1-8)	0.092	4 (2-9)	5 (2-15)	0.178

FU, follow-up; ICP; intracranial pressure; mGCS, motor Glasgow Coma Scale; Nonop, nonoperative treatment; SEPS; subdural evacuation port system; SSRF, surgical stabilization of rib fractures; ICP, intracranial pressure; TBI; traumatic brain injury.

*: provides the exact number of patients for which the outcome measure was known.

Data are shown as N (%), mean (SD), or as median (P_{25}-P_{75}); bold p-values are considered statistically significant

Supplemental Table S1: Demographics and injury characteristics of patients with moderate (GCS 9-12) or severe (GCS ≤8) traumatic brain injury (TBI) and rib fractures treated operatively (SSRF) or nonoperatively

	Moderate TBI					Severe TBI				
	N*	**SSRF (n=35)**	**N***	**Nonoperative (n=62)**	**P-value**	**N***	**SSRF (n=76)**	**N***	**Nonoperative (n=283)**	**P-value**
Patient characteristics										
Age (years)	35	56 (SD 16.2)	62	53 (SD 17.1)	0.468	76	46 (SD 14.2)	283	49 (SD 16.8)	0.208
Sex (male)	35	24 (68.6%)	62	52 (83.9%)	0.122	75	56 (74.7%)	283	217 (76.7%)	0.761
BMI (kg/m^2)	29	27 (24-33)	53	26 (24-31)	0.380	71	28 (25-31)	245	26 (23-29)	**0.014**
Smoking at age of trauma	24	7 (29.2%)	45	17 (37.8%)	0.598	59	31 (52.5%)	200	76 (38.0%)	0.051
COPD	35	5 (14.3%)	62	2 (3.2%)	0.094	76	6 (7.9%)	283	14 (4.9%)	0.395
Diabetes Mellitus	35	2 (5.7%)	62	5 (8.1%)	1.000	76	12 (15.8%)	283	30 (10.6%)	0.229
Injury characteristics										
High-energy trauma (HET)	35	30 (85.7%)	61	55 (90.2%)	0.522	75	70 (93.3%)	279	253 (90.7%)	0.646
Epidural hematoma	35	3 (8.6%)	62	4 (6.5%)	0.700	76	3 (3.9%)	283	28 (9.9%)	0.112
Subdural hematoma	35	15 (42.9%)	62	36 (58.1%)	0.204	76	26 (34.2%)	283	166 (58.7%)	**<0.001**
Subarachnoid hemorrhage	35	17 (48.6%)	62	39 (62.9%)	0.202	76	43 (56.6%)	283	201 (71.0%)	**0.019**
Diffuse axonal injury (DAI)	35	4 (11.4%)	62	4 (6.5%)	0.454	76	17 (22.4%)	283	65 (23.0%)	1.000

Intra-parenchymal hemorrhage	35	10 (28.6%)	62	18 (29.0%)	1.000	76	24 (31.6%)	283	80 (28.3%)	0.572
Intraventricular hemorrhage	35	0 (0.0%)	62	0 (0.0%)	N.D.	76	5 (6.6%)	283	35 (12.4%)	0.217
Brain contusion	35	8 (22.9%)	62	5 (8.1%)	0.061	76	18 (23.7%)	283	38 (13.4%)	**0.034**
Intracranial hypertension (ICH)	35	0 (0.0%)	61	5 (17.2%)	0.141	76	11 (22.0%)	275	65 (35.7%)	0.088
Number of ribs fractured	35	9 (8-12)	62	8 (6-10)	**0.023**	76	9 (8-12)	283	8 (5-11)	**<0.001**
Injury Severity Score (ISS)	35	29 (24-36)	62	29 (24-36)	0.961	76	34 (29-43)	283	34 (27-41)	0.596
Additional injury										
Flail chest	35	24 (68.6%)	59	19 (32.2%)	**0.001**	76	62 (81.6%)	279	116 (41.6%)	**<0.001**
Pneumothorax	35	28 (80.0%)	62	42 (67.6%)	0.242	76	66 (86.8%)	283	210 (74.2%)	**0.021**
Hemothorax	35	22 (62.9%)	62	33 (53.2%)	0.399	75	45 (60.0%)	282	146 (51.8%)	0.241
Pulmonary contusion	35	25 (71.4%)	62	44 (71.0%)	1.000	76	60 (78.9%)	279	208 (74.6%)	0.457
Facial fracture	35	10 (28.6%)	62	22 (35.5%)	0.511	76	31 (40.8%)	283	106 (37.5%)	0.597
Skull fracture	35	9 (25.7%)	61	21 (34.4%)	0.493	76	33 (43.4%)	283	123 (43.5%)	1.000
Fracture in every rib region	33	13 (39.4%)	54	18 (33.3%)	0.647	67	35 (52.2%)	251	75 (29.9%)	**0.001**
≥100% displacement of ≥3 ribs	34	27 (79.4%)	61	43 (70.5%)	0.467	75	54 (72%)	271	177 (65.3%)	0.333
Treatment characteristics										
Chest tube required	35	32 (91.4%)	62	38 (61.3%)	**0.002**	76	67 (88.2%)	283	193 (68.2%)	**<0.001**
ICP reducing therapy required	35	2 (5.7%)	62	18 (29.0%)	**0.008**	76	24 (31.6%)	283	128 (45.2%)	**0.037**
Mannitol	35	1 (2.9%)	62	9 (14.5%)	0.089	76	11 (14.5%)	283	50 (17.7%)	0.607

Hypertonic saline	35	1 (2.9%)	62	11 (17.7%)	0.051	76	9 (11.8%)	283	56 (19.8%)	0.132
Ventriculostomy	35	0 (0.0%)	62	4 (6.5%)	0.293	76	10 (13.2%)	283	52 (18.4%)	0.311
SEPS drain	35	0 (0.0%)	62	0 (0.0%)	N.D.	76	0 (0.0%)	283	3 (1.1%)	1.000
Pentobarbital/Nembutal	35	0 (0.0%)	62	3 (4.8%)	0.551	76	5 (6.6%)	283	24 (8.5%)	0.813
Craniotomy	35	0 (0.0%)	62	6 (9.7%)	0.084	76	4 (5.3%)	283	46 (16.3%)	**0.014**
Anti-epileptics	35	1 (2.9%)	62	1 (1.6%)	1.000	76	0 (0.0%)	283	7 (2.5%)	0.353
Additional surgeries performed										
Facial surgery	35	4 (11.4%)	62	4 (6.5%)	0.454	76	9 (11.8%)	283	17 (6.0%)	0.131
Clavicle surgery	35	1 (2.9%)	62	0 (0.0%)	0.361	76	7 (9.2%)	283	8 (2.8%)	**0.022**
Thoracotomy	35	2 (5.7%)	62	2 (3.2%)	0.618	76	6 (7.9%)	283	9 (3.2%)	0.099
Laparotomy	35	4 (11.4%)	62	6 (9.7%)	1.000	76	7 (9.2%)	283	37 (13.1%)	0.435
Pelvic surgery	35	1 (2.9%)	62	8 (12.9%)	0.150	76	10 (13.2%)	283	27 (9.5%)	0.395
Long bone surgery	35	11 (31.4%)	62	10 (16.1%)	0.122	76	22 (28.9%)	283	66 (23.3%)	0.367
Spine surgery	35	2 (5.7%)	62	8 (12.9%)	0.321	76	4 (5.3%)	283	32 (11.3%)	0.136

BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; GCS, Glasgow Coma Scale; ICP, intracranial pressure; N.D., not determined; SEPS, subdural evacuation port system; SSRF, surgical stabilization of rib fractures; TBI, traumatic brain injury.

*: provides the exact number of patients for which the parameter was known

Data are shown as mean (SD), N (%), or as median (P_{25}-P_{75}); bold p-values are considered statistically significant.